Conclusion The current systematic review and meta- analysis showed that the long-term consumption of CLA increases the levels of CRP and Lp(a )
Background C-reactive protein ( CRP ) and lipoprotein ( a ) ( Lp[a ] ) play essential roles in cardiovascular disease incidence .
This study aim ed to review the association between the intake of conjugated linoleic acid ( CLA ) in the form of dietary supplement or enriched food with different treatment duration s and the levels of Lp(a ) and CRP in human studies .
Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans.
After 12 mo in a r and omized , double-blind , placebo-controlled trial of conjugated linoleic acid ( CLA ) supplementation ( 2 groups received CLA as part of a triglyceride or as the free fatty acid , and 1 group received olive oil as placebo ) , 134 of the 157 participants who concluded the study were included in an open study for another 12 mo . The goals of the extension study were to evaluate the safety [ with clinical chemistry analyses and reported adverse events ( AEs ) ] and assess the effects of  CLA on body composition [ body fat mass ( BFM ) , lean body mass ( LBM ) , bone mineral mass ( BMM ) ] , body weight , and BMI . All subjects were supplemented with 3.4 g CLA/d in the triglyceride form . Circulating lipoprotein(a ) and thrombocytes increased in all groups . There was no change in fasting blood glucose . Aspartate amino transferase , but not alanine amino transferase , increased significantly . Plasma total cholesterol and LDL cholesterol were reduced , whereas HDL cholesterol and triglycerides were unchanged . The AE rate decreased compared with the first 12 mo of the study . Body weight and BFM were reduced in the subjects administered the placebo during the initial 12 mo study ( -1.6 + /- 3.2 and -1.7 + /- 2.8 kg , respectively ) . No fat or body weight changes occurred in the 2 groups given CLA during the initial 12 mo . LBM and BMM were not affected in any of the groups . Changes in body composition were not related to diet and /or training . In conclusion , this study shows that CLA supplementation for 24 mo in healthy , overweight adults was well tolerated . It confirms also that CLA decreases BFM in overweight humans , and may help maintain initial reductions in BFM and weight in the long term
Conclusion The current systematic review and meta- analysis showed that the long-term consumption of CLA increases the levels of CRP and Lp(a )
Background C-reactive protein ( CRP ) and lipoprotein ( a ) ( Lp[a ] ) play essential roles in cardiovascular disease incidence .
This study aim ed to review the association between the intake of conjugated linoleic acid ( CLA ) in the form of dietary supplement or enriched food with different treatment duration s and the levels of Lp(a ) and CRP in human studies .